| Name | Title | Contact Details |
|---|---|---|
Peter Vladimirov |
Chief Technology Officer | Profile |
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
PHNS provides comprehensive information technology and business process services to hospitals, healthcare providers and other businesses across the United States.
PeproTech is a Rocky Hill, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United! International Laboratories is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
zuChem is a leading producer of unique sugars for human health and nutrition. zuChem develops proprietary technologies for the manufacture of glycochemicals and carbohydrates for use in the food, specialty and fine chemical markets. The zuChem approach is unique, combining new proprietary technologies with the more traditional synthetic techniques. zuChem researchers have a proven track record in developing and implementing scalable, industrial quality processes.